In tumors with mutant p53, targeting of mutant p53—for example, by selective degradation or inhibition—is vigorously investigated to counteract the DNE or GOF function of mutant p53 to overcome the cancer growth-promoting effect of mutant p53. This evidence concerns the gene TP53 and cancer.